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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effect of different tests, protocols or guidelines for investigating and identifying the causes of stillbirth on outcomes for
parents, including psychosocial outcomes, on rates of diagnosis of the causes of stillbirth, and on costs.
B A C K G R O U N D
Description of the condition
Stillbirth is associated with profound and long-lasting adverse psy-
chosocial outcomes for families and care providers, along with
wider economic impacts on health systems and society (Heazell
2016). The global burden of stillbirth is high, with an estimated
2.6 million stillbirths (at 28 weeks’ gestation or greater) occurring
every year. Although many of these deaths are preventable, global
reduction in stillbirth rates remains slow and has not matched de-
clines in maternal or child mortality (Lawn 2016).
Accurate data on causes of stillbirth are limited, partly due to the
difficulty in assigning causation owing to the often multifacto-
rial circumstances (Silver 2007; Whitfield 1986). The use of var-
ious, disparate classification systems for assigning cause of death
also hampers understanding of causes at the global level (Flenady
2015; Leisher 2016;Wojcieszek 2016). A recent systematic review
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(Flenady 2016), showed wide variation in the reported contribu-
tion of different causes of stillbirth. For example, the proportion
of stillbirths related to infection ranged from 5% to 22%, and the
proportion of stillbirths related to congential abnormalities ranged
from 6% to 27%. “Unexplained” deaths were reported for up to
76% of cases, and showed particularly wide variation.
Difficulties ascertaining causes of death are often compounded by
limited availability of clinical information. In some low- and mid-
dle-income countries (LMICs), minimal or no diagnostic investi-
gations are available (Flenady 2010).Despite these limitations, it is
clear that over half of stillbirths globally are related to intrapartum
complications, and that increased access to skilled birth attendants
and emergency obstetric care could eliminate the majority of these
deaths (Lawn 2016). Infection (such as malaria and syphilis) and
placental conditions (such as fetal growth restriction (FGR), pla-
cental abruption, andpre-eclampsia) are other commonly reported
causes of stillbirth. Pre-existing hypertension and diabetes are also
important and common risk factors for stillbirth. These risk fac-
tors are often associated with obesity and advanced maternal age,
which are independent risk factors for stillbirth that are increas-
ingly common throughout the developed world (Flenady 2011).
Other major risk factors for stillbirth include smoking, multiple
pregnancy, previous stillbirth, primiparity (Flenady 2011), and
post-term pregnancy (Flenady 2011; Lawn 2016).
Although the burden of stillbirth lies predominantly in LMICs,
thousands of potentially preventable stillbirths also occur in high-
income countries (HICs) (Flenady 2016). In these settings, the
majority of stillbirths occur in the antenatal period, and are asso-
ciated with placental dysfunction (Flenady 2016). Disparities in
stillbirth rates are clearly evident, with the risk of stillbirth among
disadvantaged women roughly double that among more advan-
taged women (Flenady 2016).
Description of the intervention
To enable focused strategies to reduce stillbirth rates, accurate de-
termination of causes and contributing factors is needed. To iden-
tify causes of death, collection of data related to the stillbirth, such
as demographic data, maternal risk factors and labour and birth
information is required (Barfield 2011; Flenady 2009). A range
of diagnostic investigations, as described in further detail below,
may also be recommended.
This review focusses on interventions for investigating and iden-
tifying the causes of stillbirth. Such interventions are likely to be
diverse, but may include, for example:
• review of maternal and family history, and current
pregnancy history;
• clinical history of present illness;
• maternal investigations (such as ultrasound, amniocentesis,
antibody screening, blood grouping, etc);
• examination of the stillborn baby (including full-autopsy,
partial autopsy or non-invasive components, such as magnetic
resonance imaging (MRI), computerised tomography (CT)
scanning, and radiography);
• umbilical cord examination;
• placental examination (including histopathology); and
• verbal autopsy (interviews with care providers and support
people to ascertain causes without examination of the baby).
Among the investigations listed, autopsy is considered the ’gold
standard’ in determining causes of death (Alderliesten 2003; Lyon
2004; Rose 2006). Autopsy can identify a wide range of causes
of stillbirth, including infection, anaemia, and morphologic and
metabolic abnormalities (Silver 2007). However, there is varia-
tion in the reported yield of the procedure following a stillbirth
(Gordijn 2002). Further, many factors influence parents’ decision
regarding whether to consent to or decline autopsy (Breeze 2012),
and some parents may decline the examination to avoid subjecting
their baby to invasive examination (Lyon 2004). Cultural and re-
ligious practices, such as the requirement of prompt burial and/or
for the baby’s body to be left undisturbed, may also influence deci-
sion-making (Gordijn 2007).While some parents later regret hav-
ing or not having an autopsy of their baby (Heazell 2012; Rankin
2002), there are currently no interventions to support parents’ de-
cision-making around this procedure (Horey 2013). Medical per-
sonnel are often reluctant to approach parents about autopsy for
various reasons, including emotional burden (Khong 2010; Rose
2006) and/or because they do not believe the investigation will
yield any new information (Lyon 2004; Rose 2006). Therefore,
when full autopsy is not possible, alternative investigations such
as fetal CT scan, fetal radiography (Lim 2005), and fetal MRI
(Alderliesten 2003; Arthurs 2015) may be performed.
Alongside autopsy, examination of the placenta and testing for
chromosomal abnormalities have shown high value in ascertain-
ing causes of death (Bukowski 2011; Korteweg 2008; Korteweg
2012). Other investigations that may be included in the routine
evaluation of stillbirth include (but are not limited to) maternal
thyroid, liver and kidney function tests, testing for gestational di-
abetes (Flenady 2009), toxicology screening (to detect maternal
drug use), and tests for various infections and viruses (Silver 2007).
Investigations to identify maternal antibodies and blood clotting
disorders (thrombophilias) may be valuable in some situations.
As stated above, the ability to undertake certain investigations may
be extremely limited in LMICs due to a lack of resources (Flenady
2010). In these settings, verbal autopsy (involving interviews with
care providers and support people as stated above, without exam-
ination of the baby) may be relied upon as an indirect method of
ascertaining cause of death (Nausheen 2013). Therefore, it is also
important to identify which tests are feasible in a setting where
cost and access to equipment are barriers.
How the intervention might work
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A high-quality investigation into the causes of stillbirth will ide-
ally place minimal emotional and financial burden on parents,
staff, and health services, while maintaining high diagnostic yield
(Corabian 2005; Lim 2005; Silver 2007). A number of formal
protocols are currently in use to standardise investigations fol-
lowing stillbirth, but there is large variation in the recommended
investigations (Corabian 2005). A specific comprehensive inves-
tigation protocol has previously been shown to be cost-effective
when incorporated into routine stillbirth evaluation (Michalski
2002). Comprehensive investigations protocols may be advan-
tageous where there are multiple, interacting causes which may
not otherwise be detected (Silver 2007). Another approach to
the workup of stillbirth is selective testing, where investigations
are undertaken based on clinical features and presumed diagnosis
(Flenady 2010; Lim 2005). A selective approach to investigations
may reduce costs (Lim 2005), while also minimising the chance
of producing positive test results that cause anxiety among parents
and are unhelpful in ascertaining a cause of death (Korteweg 2012;
Silver 2007). Sequential testing, where tests are undertaken based
on the results of other tests, has been proposed as another alter-
native (Flenady 2010; Korteweg 2012). This approach suggests a
platform of basic tests with follow-up investigations undertaken
as indicated (Korteweg 2012). For example, while routine throm-
bophilia testing is not commonly recommended, it may be con-
sidered in cases where there is evidence of placental complications,
such as FGR (Korteweg 2010; Silver 2007).
High-quality tests, protocols or guidelines for investigating and
identifying the causes of stillbirth have substantial potential to re-
duce the number of unexplained deaths and misdiagnosed causes
of death. Investigations may also have value in confirming clinical
diagnoses, providing additional information that may not have
been expected clinically (Gordijn 2002; Horn 2004), and/or ex-
cluding specific causes of death (Horn 2004; Korteweg 2012).
Relying solely on death certificates to identify causes of death is
problematic, as death certificates are not required for stillbirths
in many LMICs (Flenady 2015). Even in developed settings, the
causes of death documented on death certificates are frequently
inaccurate (Cockerill 2012; Headley 2009; Measey 2007). Retro-
spective cohort studies have shown that the proportion of deaths
initially classified as unexplained can be reduced by up to 65%
following investigation and clarification (Headley 2009; Measey
2007).
Accurate identification of causes of stillbirth not only aids par-
ents’ emotional closure, it provides a platform for clinical manage-
ment in subsequent pregnancies (Flenady 2009; Michalski 2002;
Silver 2007). Indeed, the need for information for planning of
future pregnancies is one of the most important factors that influ-
ences parents’ decision regarding whether to have an autopsy of
their baby (Breeze 2012). The identification of a known recurrent
cause of death, or a death unexplained despite thorough investi-
gation, may prompt additional testing and surveillance in subse-
quent pregnancies (Mistry 2013). In contrast, the identification of
a known non-recurrent cause may reassure parents and spare them
from unnecessary testing and intervention in subsequent pregnan-
cies (Silver 2007). A recent UK study showed pregnancies sub-
sequent to stillbirths that were unexplained or had known recur-
rent causes were £500 more costly than pregnancies subsequent to
stillbirths due to known non-recurrent causes (Mistry 2013). The
study suggested that while a comprehensive workup of stillbirth
may bring a higher initial cost to health systems, the costs of care
in subsequent pregnancies may be reduced if investigations can
exclude recurrent causes and reduce unexplained deaths (Mistry
2013). Importantly, the quality of the postmortem investigation
and report, regardless of the investigations performed, will impact
on the likelihood of yielding clinically meaningful information
(Cartlidge 1995; Corabian 2005).
Why it is important to do this review
At the heart of the prevention of stillbirth is understanding of its
causes. Diagnostic investigations aim to meet this need, but there
is currently no consensus on the optimal approach to the inves-
tigation of stillbirth (Korteweg 2012; Lim 2005). Accurate iden-
tification of the causes of stillbirth is of paramount importance,
given that additional knowledge may allow informed counselling
for parents about recurrence risks, and assist in the management
of subsequent pregnancies. A wide variety of investigations are
potentially available for the investigation of stillbirth. However,
given their economic cost, and their potential to add further emo-
tional burden to parents, there is a need to systematically assess the
effect of these interventions on outcomes for parents, including
psychosocial outcomes, and on rates of diagnosis of the causes of
stillbirth.
O B J E C T I V E S
To assess the effect of different tests, protocols or guidelines for
investigating and identifying the causes of stillbirth on outcomes
for parents, including psychosocial outcomes, on rates of diagnosis
of the causes of stillbirth, and on costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Weplan to include randomised controlled trials, quasi-randomised
controlled trials and cluster-randomised trials. We plan to exclude
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cross-over trials. We plan to include studies published as abstract
only, provided there is sufficient information to allow us to assess
study eligibility.
Types of participants
The participants will be parents (including mothers, fathers, and
partners) who have experienced a stillbirth of 20 weeks’ gestation
or greater.
Types of interventions
We will include trials assessing any test, protocol or guideline (or
combinations of tests/protocols/guidelines) for investigating the
causes of stillbirth, comparedwith the absence of a test, protocol or
guideline, or usual care (see above Description of the intervention
for further details as to the types of tests or investigations that
might be included in such protocols/guidelines).
Wewill also include trials comparing any test, protocol or guideline
(or combinations of tests/protocols/guidelines) for investigating
the causes of stillbirth with another (for example, the use of a
limited investigation protocol compared with a comprehensive
investigation protocol).
Types of outcome measures
No core outcomes were identified for this review topic. We there-
fore selected a range of important outcomes with respect to the
effects of investigations.
Primary outcomes
• Change in the final cause(s) of death from the presumed or
clinical a priori cause of death
• Final cause(s) of death unknown
• Additional parental counselling or subsequent pregnancy
care information (e.g. determination of or change in recurrence
risk; exclusion of suspected causes of death; exclusion of
recurrent causes of death; or combination of these)
• Parental satisfaction with the process and outcomes of
investigations
Secondary outcomes
In postpartum period
• Confirmation of clinical diagnosis
• Attainment of unexpected findings
• Exclusion of suspected causes of death
• Exclusion of recurrent causes of death
• Compliance with test/protocol/guideline
• Parental understanding of the cause(s) of death
• Parental regret about the investigations performed
• Parental attitudes towards process and outcomes of
investigations
• Parental psychosocial outcomes including anxiety and
quality of life
• Parental satisfaction with care around the time of death and
at follow-up
• Care provider satisfaction with the process and outcomes of
investigations
• Frequency of investigations performed, e.g. maternal and
family history; maternal investigations prior to delivery; stillborn
examination; umbilical cord examination; placental examination
• Costs of investigations
In subsequent pregnancy
• Stillbirth
• Neonatal death
• Preterm birth
• Induction of labour
• Caesarean birth
• Low birthweight
• Parental anxiety
• Costs of the subsequent pregnancy
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We will search Cochrane Pregnancy and Childbirth’s Trials Regis-
ter by contacting their Information Specialist.
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about Cochrane Pregnancy and Childbirth in
theCochrane Library and select the ‘Specialized Register ’ section
from the options on the left side of the screen.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
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5. handsearches of 30 journals and the proceedings of major
conferences; and
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in amore specific search set that will be fully
accounted for in the relevant review sections (Included, Excluded,
Awaiting Classification or Ongoing).
In addition, we will search ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned and ongoing trial reports using the terms given in
Appendix 1.
Searching other resources
We will search the reference lists of retrieved studies for further
eligible studies.Wewill not apply any date or language restrictions.
Data collection and analysis
The following methods will be used for assessing studies identified
by the search.
Selection of studies
Two review authors will independently assess for inclusion all the
potential studies we identify as a result of the search strategy. We
will resolve any disagreement through discussion or, if required,
we will consult a third review author.
We will create a Study flow diagram to map out the number of
records identified, included and excluded.
Data extraction and management
We will design a form to extract data. For eligible studies, two
review authors will extract the data using the agreed form. We
will resolve discrepancies through discussion or, if required, we
will consult a third review author. We will enter data into Review
Manager software (RevMan 2014) and check for accuracy. When
information regarding any of the above is unclear, we will attempt
to contact authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
any disagreement by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
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(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
Assessing the quality of the evidence using the GRADE
approach
We will use the GRADE approach as outlined in the GRADE
handbook in order to assess the quality of the body of evidence
relating to the following outcomes for the main comparisons:
• change in the final cause(s) of death from the presumed or
clinical a priori cause of death;
• final cause(s) of death unknown;
• additional parental counselling or subsequent pregnancy
care information (e.g. determination of or change in recurrence
risk; exclusion of suspected causes of death; exclusion of
recurrent causes of death; or combination of these);
• parental satisfaction with the process and outcomes of
investigations;
• compliance with test/protocol/guideline;
• costs of investigations; and
• stillbirth (in the subsequent pregnancy).
We will use the GRADEpro Guideline Development Tool to im-
port data from Review Manager 5.3 (RevMan 2014) in order to
create ’Summary of findings’ tables. A summary of the interven-
tion effect and a measure of quality for each of the above outcomes
will be produced using the GRADE approach. The GRADE ap-
proach uses five considerations (study limitations, consistency of
effect, imprecision, indirectness and publication bias) to assess the
quality of the body of evidence for each outcome. The evidence
can be downgraded from ’high quality’ by one level for serious (or
by two levels for very serious) limitations, depending on assess-
ments for risk of bias, indirectness of evidence, serious inconsis-
tency, imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk
ratio with 95% confidence intervals.
Continuous data
For continuous data, we will use the mean difference if outcomes
are measured in the same way between trials. We will use the
standardised mean difference to combine trials that measure the
same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually-randomised trials. We will adjust their sample sizes
using the methods described in the Handbook using an estimate
of the intracluster correlation co-efficient (ICC) derived from the
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trial (if possible), from a similar trial or from a study of a similar
population. If we use ICCs from other sources, we will report this
and conduct sensitivity analyses to investigate the effect of varia-
tion in the ICC. If we identify both cluster-randomised trials and
individually-randomised trials, we plan to synthesise the relevant
information. We will consider it reasonable to combine the re-
sults from both if there is little heterogeneity between the study
designs and the interaction between the effect of intervention and
the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
We plan to include multi-armed trials, ensuring analyses are in-
dependent. If multi-armed trials are included, we will split the
‘shared’ group into two or more groups with smaller sample size,
and include two or more (reasonably independent) comparisons.
Alternatively, we will combine groups to create a single pair-wise
comparison.
Cross-over trials
We will exclude cross-over designs as these are unlikely to be a
valid study design for Pregnancy and Childbirth reviews.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis, i.e. we will attempt to include all
participants randomised to each group in the analyses, and all
participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial
will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We will regard heterogeneity as
substantial if an I² is greater than 30%and either the Tau² is greater
than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
We will carry out statistical analysis using the Review Manager
software (RevMan 2014). We will use fixed-effect meta-analysis
for combining datawhere it is reasonable to assume that studies are
estimating the same underlying treatment effect: i.e. where trials
are examining the same intervention, and the trials’ populations
and methods are judged sufficiently similar. If there is clinical het-
erogeneity sufficient to expect that the underlying treatment ef-
fects differ between trials, or if substantial statistical heterogeneity
is detected, we will use random-effects meta-analysis to produce
an overall summary, if an average treatment effect across trials is
considered clinically meaningful. The random-effects summary
will be treated as the average of the range of possible treatment
effects and we will discuss the clinical implications of treatment
effects differing between trials. If the average treatment effect is
not clinically meaningful, we will not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of Tau² and I².
We plan to consider separately those trials assessing any test/pro-
tocol or guideline (or combinations of tests/protocols/guidelines)
compared with no test/protocol/guideline or usual care, and those
comparing different tests/protocols/guidelines.
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it us-
ing subgroup analyses and sensitivity analyses. We will consider
whether an overall summary is meaningful, and if it is, use ran-
dom-effects analysis to produce it.
We plan to carry out the following subgroup analyses across the
primary outcomes:
• number and type of investigations included in the protocol/
guideline (e.g. single/limited investigation(s) recommended
versus multiple/comprehensive investigations recommended);
• quality of the autopsy/postmortem report (e.g. low quality
versus high quality, or not meeting a minimum standard versus
meeting a minimum standard);
• presumed cause(s) of death prior to investigations:
unexplained stillbirth at time of death versus stillbirth with
known/presumed cause(s);
• gestational age at death: death at less than 28 weeks’
gestation versus at 28 weeks’ gestation or greater;
• setting: LMICs versus HICs; and
• classification systems used.
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2014). We will report the results of
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subgroup analyses quoting the Chi2 statistic and P value, and the
interaction test I² value.
Sensitivity analysis
Sensitivity analyses will be conducted to explore the effects of trial
quality and trial design on the outcomes. We will explore the ef-
fects of trial quality assessed by allocation concealment and ran-
dom sequence generation (considering selection bias), by omitting
studies rated as ’high risk of bias’ (including quasi-randomised tri-
als) or ’unclear risk of bias’ for these components.
We will investigate the effects of the randomisation unit (individ-
ual versus cluster) on the outcomes, and the impact of including
studies with high levels of missing data. We will explore the ef-
fects of fixed-effect or random-effects analyses for outcomes with
statistical heterogeneity, and the effects of any assumptions made
such as the value of the ICC used for cluster-randomised trials.
We will use primary outcomes in sensitivity analyses.
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A P P E N D I C E S
Appendix 1. Search terms for ICTRP and ClinicalTrials.gov
We will run each line separately and deduplicate manually:
stillbirth AND cause
stillbirth AND causes
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